Developing and applying clinically useful approaches to identify individuals with familial hypercholesterolemia in the UK

Clinical Lipidology

Volumn 5, Issue 4, 2010, Pages 497-507

  Humphries, Steve E ^b   Neil, H Andrew W ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NONE

Author keywords

cascade testing; detection; nDNA; testing nearly

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; ROSUVASTATIN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ELECTRONIC MEDICAL RECORD; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; FEASIBILITY STUDY; GENE MUTATION; GENETIC ANALYSIS; HEALTH PROGRAM; HUMAN; INFORMATION RETRIEVAL; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; NATIONAL HEALTH SERVICE; PATIENT CARE; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; UNITED KINGDOM;

EID: 77955579498     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.39     Document Type: Review

References (50)

1. Marks D, Thorogood M, Neil HA, Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168(1), 1-14 (2003).
2. Slack J: Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 2(7635), 1380-1382 (1969).
3. Patterson D, Slack J: Lipid abnormalities in male and female survivors of myocardial infarction and their first-degree relatives. Lancet 1(7747), 393-399 (1972).
4. Scientific Steering Committee on behalf of The Simon Broome Register Group: The risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 303(6807), 893-896 (1991).
5. DeMott K, Nherera L, Shaw EJ et al.: Clinical Guidelines and Evidence Review for Familial Hypercholesterolaemia: the Identification and Management of Adults and Children with Familial Hypercholesterolaemia. National Collaborating Centre for Primary Care and Royal College of General Practitioners, London, UK (2008).
6. Wierzbicki AS, Humphries SE, Minhas R: Familial hypercholesterolaemia: summary of NICE guidance. BMJ (337), A1095 (2008).
7. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ: Review of first 5 years of screening for familial hypercholesterolaemia in The Netherlands. Lancet 357(9251), 165-168 (2001).
8. Pocovi M, Civeira F, Alonso R, Mata P: Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin. Vasc. Med. 4(1), 67-74 (2004).
9. Leren TP, Manshaus T, Skovholt U et al.: Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin. Vasc. Med. 4(1), 75-85 (2004).
10. Gaudet D, Vohl MC, Couture P et al.: Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men. Atherosclerosis 143(1), 153-161 (1999).
11. National Cholesterol Education Program Laboratory Standardization Panel: Current status of blood cholesterol measurement in clinical laboratories in the United States. Clin. Chem. 34(1), 193-201(1988).
12. Friedewald WT, Levi RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol concentration in plasma without use of preparative ultracentrifuge. Clin. Chem. 18(6), 499-502(1972).
13. Kwiterovich PO Jr, Fredrickson DS, Levy RI: Familial hypercholesterolaemia (one form of type II hyperlipoproteinaemia). A study of its biochemical, genetic and clinical presentation in childhood. J. Clin. Invest. 53(5), 1237-1249 (1974).
14. Leonard JV, Whitelaw AG, Wolff OH, Lloyd JK, Slack J: Diagnosing familial hypercholesterolaemia in childhood by measuring serum cholesterol. BMJ 1, 1566-1568 (1977).
15. Williams RR, Hunt SC, Schumacher MC et al.: Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72(2), 171-176 (1993).
16. Damgaard D, Larsen ML, Nissen PH et al.: The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 180(1), 155-160 (2005).
17. Hadfield SG, Horara S, Starr BJ et al.: Are patients with familial hypercholesterolaemia well managed in lipid clinics? An audit of eleven clinics from the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann. Clin. Biochem. 45(Pt 2), 199-205 (2008).
18. Starr B, Hadfield SG, Hutten BA et al.: Development of sensitive and specific age-and gender-specific low density lipoprotein cholesterol cut-offs for diagnosis of first-degree relatives with familial hypercholesterolaemia in cascade testing. Clin. Chem. Lab. Med. 46(6), 791-803 (2008).
19. Soutar AK, Naoumova RP: Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med. 4(4), 214-225(2007).
20. Varret M, Abifadel M, Rabes JP, Boileau C: Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin. Genet. 73(1), 1-13 (2008).
21. Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE: Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann. Hum. Genet. 72(Pt 4), 485-498 (2008).
22. Humphries SE, Whittall RA, Hubbart CS et al.: Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk. J. Med. Genet. 43(12), 943-949 (2006).
23. Taylor A, Patel K, Tsedeke J, Humphries SE, Norbury G: Mutation screening in patients for familial hypercholesterolaemia (ADH). Clin. Genet. 77(1), 97-99 (2010).
24. Graham CA, McIlhatton BP, Kirk CW et al.: Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate. Atherosclerosis 182(2), 331-340 (2005).
25. Wright WT, Heggarty SV, Young IS et al.: Multiplex MassARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin. Genet. 74(5), 463-468 (2008).
26. Tejedor D, Castillo S, Mozas P et al.: Comparison of DNA array platform vs DNA sequencing as genetic diagnosis tools for familial hypercholesterolemia. Clin. Chem. 52, 1971-1972 (2006).
27. Taylor A, Wang D, Patel K et al.: Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin. Genet. 77, 572-580 (2010).
28. Ng SB, Buckingham KJ, Lee C et al.: Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 42(1), 30-35 (2010).
29. Nherera L, Calvert NW, DeMott K et al.: Cost effectiveness analysis of the use of a high intensity statin compared to a low intensity statin in the management of patients with familial hypercholesterolaemia. Curr. Med. Res. Opin. 26(3), 529-536 (2010).
30. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis. 142(1), 105-112 (1999).
31. Neil A, Cooper J, Betteridge DJ et al.: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur. Heart J. 29(21), 2625-2633 (2008).
32. Huxley RR, Hawkins MH, Humphries SE, Karpe F, Neil HAW; for the Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering Committee: Risk of fatal stroke in patients with treated familial hypercholesterolemia. Stroke 34(1), 22-25 (2003).
33. Wiegman A, de Groot E, Hutten BA et al.: Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 363(9406), 369-370 (2004).
34. Wiegman A, Hutten BA, de Groot E et al.: Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292(3), 377-378 (2004).
35. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA: Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ 324(7349) 1303(2002).
36. LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352(14), 1425-1435 (2005).
37. Pedersen TR, Faergeman O, Kastelein JJ et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294(19), 2437-2445 (2005).
38. Minhas R, Humphries SE, Qureshi N, Neil HA; on behalf of the NICE Guideline Development Group: Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart 95(7), 584-587 (2009).
39. Hadfield SG, Horara S, Starr BJ et al.: Steering Group for the Department of Health Familial Hypercholesterolaemia Cascade Testing Audit Project. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem. 46(Pt 1), 24-32 (2009).
40. Gale CP, Manda SO, Weston CF, Birkhead JS, Batin PD, Hall AS: Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database. Heart 95(3), 221-227 (2009).
41. Gray J, Jaiyeola A, Whiting M, Modell M, Wierzbicki AS: Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart 94(6), 754-758 (2008).
42. Wald DS, Bestwick JP, Wald NJ: Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 335(7620), 599 (2007).
43. Hadfield GS, Humphries SE: Familial hypercholesterolaemia: cascade testing is tried and tested and cost effective. BMJ 335(7622), 683 (2007).
44. Bhatnagar D, Morgan J, Siddiq S, Mackness MI, Miller JP, Durrington PN: Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ 321(7275), 1497-1500 (2000).
45. Marks D, Thorogood M, Neil SM, Humphries SE, Neil HA: Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J. Med. Screen. 13(3), 156-159 (2006).
46. Marteau T, Senior V, Humphries SE et al.: Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am. J. Med. Genet. A 128A(3), 285-293 (2004).
47. Tonstad S, Vollebaek LE, Oxe L: Screening for familial hypercholesterolaemia in relatives. Lancet 346(8987), 1438 (1995).
48. Andersen LK, Jensen HK, Juul S, Gaergeman O: Patient attitudes to detection of heterozygous familial hypercholesterolaemia. Arch. Intern. Med. 157(5), 553-560 (1997).
49. LOVD. Select database www.ucl.ac.uk/fh
50. National Clinical Audit of the Management of Familial Hypercholesterolaemia 2009: Pilot Full Report, June 2009 www.rcplondon.ac.uk/ clinical-standards/ ceeu/Current-work/Pages/fhaudit.aspx